Phase 2, Open-label Single Arm Study Of The Efficacy And Safety Of Pf-02341066 In Patients With Advanced Non-small Cell Lung Cancer (Nsclc) Harboring A Translocation Or Inversion Involving The Anaplastic Lymphoma Kinase (Alk) Gene Locus

Trial Profile

Phase 2, Open-label Single Arm Study Of The Efficacy And Safety Of Pf-02341066 In Patients With Advanced Non-small Cell Lung Cancer (Nsclc) Harboring A Translocation Or Inversion Involving The Anaplastic Lymphoma Kinase (Alk) Gene Locus

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Jan 2017

At a glance

  • Drugs Crizotinib (Primary)
  • Indications Brain metastases; Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms P1005; PROFILE-1005
  • Sponsors Pfizer
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 29 Dec 2016 Results assessing effects of varying degrees of renal impairment on crizotinib pharmacokinetics from PROFILE 1001, PROFILE 1005 and Study 1020 trials published in the Clinical Drug Investigation
    • 08 Jun 2016 Results (pooled analysis of this and other four studies, n = 746) comparing efficacy outcomes between patients receiving ceritinib and an external control group receiving crizotinib published in the Journal of Thoracic Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top